Awakn CEO Anthony Tennyson: Developing and Delivering the Next Generation of Addiction Treatments

TL;DR

Awaken Life Sciences has signed a lease for a London clinic to provide psychedelic-assisted therapy for addiction and other mental health conditions.

Transcript

welcome to this edition of inn ceo talks joining me today is anthony tennyson the ceo of awaken life sciences which trades on the neo exchange under the symbol a w k n and on the otc pink under the symbol a w k n f awaken is a biotechnology company with clinical operations which are developing and delivering psychedelic medications to treat addicti... Read More

Key Insights

• 🌐 Addiction is a significant global health issue, affecting about 20% of the global population.
• ❓ Current treatments for addiction, including alcohol and behavioral addiction, are not very effective.
• ❓ Psychedelic-assisted psychotherapy is a revolutionary approach that combines compounds like ketamine with therapy to improve treatment outcomes.
• 🚚 Awaken Life Sciences aims to develop and deliver better treatments for addiction, while also generating revenue through their clinics.
• 😒 The regulatory environment in the UK and EU enables the use of ketamine-based treatments for addiction and mental health conditions.
• 👨‍🔬 Awaken Life Sciences is focused on creating defendable intellectual property through their research and development efforts.
• 👯 The company's goal is to democratize psychedelics and make psychedelic-assisted therapy accessible to as many people as possible.

Questions & Answers

Q: What is Awaken Life Sciences' focus?

Awaken Life Sciences is focused on developing and delivering medicines to treat addiction, both substance addiction and behavioral addiction.

Q: What makes psychedelic-assisted psychotherapy different?

Psychedelic-assisted psychotherapy combines the use of compounds like ketamine with therapy sessions, creating a treatment approach that addresses the underlying root causes of addiction and mental health conditions.

Q: What regulatory environment allows Awaken Life Sciences to deliver ketamine-based treatments?

Ketamine is a schedule 2 compound in the UK and is commonly used as a painkiller, which allows Awaken Life Sciences' clinics, led by psychiatrists, to prescribe and administer ketamine for addiction and other mental health conditions.

Q: Does Awaken Life Sciences have plans for expansion?

Yes, Awaken Life Sciences plans to open a total of 20 clinics in the UK and EU by the end of 2024. They will start with three clinics in the UK and then expand to other European countries.

Summary & Key Takeaways

• Awaken Life Sciences is a biotechnology company focused on developing and delivering treatments for addiction, including substance addiction and behavioral addiction.

• The company has signed a 10-year lease to open a clinic in London that will offer psychedelic-assisted psychotherapy treatments, such as ketamine-assisted therapies.

• Addiction and mental health conditions affect a significant portion of the global population, and Awaken Life Sciences aims to provide better and more effective treatments for these conditions.